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Summary
Purpose To assess the efficacy and toxicity of liposomal daunorubicin administered as a two-hour intravenous infusion to patients with relapsed or refractory non-Hodgkin's lymphoma (NHL)
Patients and methods Eligible patients had relapsed or refractory NHL with measurable or evaluable disease, and low grade, select intermediate grade, or mantle cell pathologic types. Prior exposure to an anthracychne or anthracenedione was allowed. Liposomal daunorubicin at a dose of 100 mg/m 2 was given intravenously over a minimum of 120 minutes every 3 weeks, as a single agent
Results Thirty-three patients were accrued twenty-three (70%) had low-grade histologies, six (18%) had intermediategrade histologies (follicular large-cell and diffuse small cleaved), and four (12%) patients had mantle-cell lymphoma Eighteen (55%) had received two or more prior regimens, fourteen (42%) received a prior anthracychne A median of six cycles of liposomal daunorubicin were administered (range 1-15) Of 31 patients evaluable for response, 2 complete and 10 partial remissions were documented for a major response rate of 39% (95% confidence interval (CI)' 22%-58%). The median duration of response was 195 months (range 4.3-41.1+) Six responders (50%) had received a prior anthracychne, one responder had mantle-cell histology The major toxicities were grade 3 or 4 neutropenia in 26 patients (79%), mild to moderate nausea in
Introduction
Patients with newly diagnosed, advanced stage, low-grade non-Hodgkin's lymphoma (NHL) have a median survival of 8-10 years [1] . To date, there are no known therapies which have proven to be curative in these patients While 'watchful waiting' is initially recommended in the majority of asymptomatic patients, the gradual progression of disease necessitates eventual treatment in the vast majority of affected individuals [2] . Therapy is usually initiated for progression of disease, development of systemic 'B' symptoms, cytopenias related to lymphomatous marrow replacement, or disease that threatens vital organ function. Treatment of indolent NHL often consists of chlorambucil with or without prednisone, or a regimen of cyclophosphamide, vincnstine, and prednisone (CVP) [3, 4] . These therapies are associated with high complete response rates However, responses are not durable, and the majority of patients eventually relapse. Alternate strategies must therefore be developed.
Recently, liposomal encapsulation of various medications has been tested in an attempt to enhance activity and reduce toxicity. Early studies with liposomal encapsulation of anthracychnes showed preferential uptake in various tumors, both in animal models and in humans, with a reduced toxicity profile [5, 6] . Phase I studies conducted in patients with solid tumors and patients with AIDS-related Kaposi's sarcoma have shown that liposomal daunorubicin can be safely administered at doses up to 120 mg/m 2 every three weeks without growth factor support [7, 8] Using liposomal daunorubicin at a dose of 40 mg/m 2 given I.V. every two weeks, efficacy has been demonstrated when used as first-line therapy in AIDS-related Kaposi's sarcoma [9] . Recent studies indicate that higher doses of liposomal daunorubicin may be safety administered, either alone or when combined with high dose cytosine arabinoside in patients with relapsed leukemia [10, 11] Based on the antitumor activity demonstrated in patients with various hematologic malignancies [7] [8] [9] [10] [11] , we initiated a phase II trial in patients with refractory or relapsed low-grade or intermediate-grade NHL employing a two-hour infusion of liposomal daunorubicin administered intravenously, every three weeks
Patients and methods

Patients
This study was reviewed and approved by the Institutional Review Board from each participating institution All patients gave signed informed consent Patients with a diagnosis of relapsed or refractory low-or intermediate-grade non-Hodgkin's lymphoma, stage IE. II. Ill or IV documented immediately prior to entry on this trial were accrued The following pathologic types were allowed small lymphocytic lymphoma. all folhcular lymphomas, monocytoid B-cell lymphoma, marginal zone lymphoma, diffuse small cleaved lymphoma, and mantle-cell lymphoma Patients were required to be 18 years of age or older, with a life expectancy of > 3 months Other eligibility criteria included measurable or evaluable disease and history of prior treatment with a systemic cytotoxic agent for lymphoma Patients could have received a prior anthracyclme-or anthracenedione-containing regimen Patients were required to be off all therapy for >4 weeks prior to study entry Adequate renal (serum creatinine < 2 0 mg/dl) and hepatic function (bilirubin, alkaline phosphatase. alanine and aspartate transaminases <2 times the upper limit of normal) were required, unless abnormalities were due to lymphomatous involvement Adequate hcmalologic function (absolute neulrophil count >200O/mm 3 , platelet count > 100,000/mm 1 ) was required, unless secondary to lymphomatous infiltration of the marrow Baseline left ventricular ejection fraction (LVEF) 3:45% was also required
Study evaluations
The following evaluations were performed within four weeks of study entry medical history and physical examination, complete blood count (CBC) with differential, serum chemistries, including renal and hepatic profile, chest X-ray, electrocardiogram, computerized tomography scans of the chest, abdomen and pelvis, bone marrow aspiration and biopsy, and evaluation of LVEF by echocardiogram or MUGA scan Evaluations during the study included a physical examination. CBC. and serum chemistries prior to each dose of liposomal daunorubicin Patients were evaluated for response to therapy after every three cycles of treatment, repeating all tests that were previously positive for lymphoma at baseline Any major response (defined as complete plus partial responses) to therapy was confirmed by two measurements at least four weeks apart Patients underwent repeat evaluation for LVEF after a cumulative liposomal daunorubicin dose of 500 mg/m 2 , and after every 300 mg/m 2 thereafter
Study treatment
Patients received liposomal daunorubicin at a dose of 100 mg/m 2 which was mixed with 5% dextrose and infused intravenously over a minimum of 120 minutes Treatment cycles (l e. one dose) were repeated every three weeks, toxicity permitting Granulocyte colonystimulating factor (G-CSF) therapy was not given prophylactically with the initial dose of chemotherapy, but could be given as clinically indicated after the first appearance of neutropema Anti-emetics and other supportive care medications were allowed as clinically indicated For patients not experiencing neutropema or thrombocytopema, dose escalations by 20 mg/m 2 were permitted to a maximum dose of 140 mg/m 2 , this 140 mg/m 2 dose is the maximum tolerated dose (MTD) previously defined for liposomal daunorubicin given every three weeks from a previous phase I study [12] Toxicity and dose modification
The SouthWest Oncology Group (SWOG) toxicity grading criteria was used for this study [12] Treatment was delayed for up to one week for an absolute neutrophil count (ANC) of $ 1000/mm 1 or a platelet count < 75,000/mm 3 on the day of planned therapy Liposomal daunorubicin was resumed at full dose when the ANC rose to greater than 1000/mm 1 or platelet count was above 75,000/mm'' The dose of liposomal daunorubicin was decreased to 80 mg/m 2 if ANC or platelet recovery required up to a three-week delay For delays greater than three weeks, the patient was removed from the study Patients could receive hematopoietic growth factor support (granulocyte-colony stimulating factor G-CSF) if the absolute gTanulocyte count was less than 1000/mm 3 in the previous cycle
Response criteria
To be evaluable for response, patients had to receive at least two cycles of therapy, unless there was evidence of disease progression Complete response (CR) was defined as complete disappearance of all measurable and evaluable disease lasting >4 weeks, with development of no new lesions Partial response (PR) was defined as ^50% reduction in the cross-sectional area of all measurable sites, lasting >4 weeks with development of no new lesions Stable disease (SD) was defined as a response which did not qualify as CR, PR or progressive disease (PD) Progressive disease (PD) was defined as 3=25% increase in all measurable sites of disease compared with baseline, or development of new sites of disease at any time during therapy Duration of response was computed from the time of onset of PR or CR to the lime of relapse, last follow-up, or death
Pathology review
Central pathology review was required, and slides from the most recent diagnostic specimens were reviewed by one of the investigators (B Nathwani) Histologic classification of lymphoma was reported using the Working Formulation designations [13] Results
Patients
Patient characteristics are listed in Table 1 Twenty-three male and ten female patients were accrued The median age was 61 years (range 38-84). There were 23 Caucasians, 5 Hispanics, 4 African-Americans, and 1 Native American. At study entry, 23 (70%) patients had low grade, 6 (18%) patients had intermediate grade, and 4 (12%) patients had mantle-cell histologies The majority of patients (91%) had stage III or IV disease. Sites of extranodal lymphomatous involvement included bone marrow (n = 25), pleural effusion (n = 2), bone (n = 2); and abdominal mass, pericardial effusion, ascites and (76) 7 (21) 23 (70) 10 (30) 15 (46) 8 (24) 3 (9) 6 (18) 1 (3) 14 (42) lung in one patient each. Systemic 'B' symptoms were reported in seven patients (21%) at study entry
Prior therapy
All patients had either relapsed after initial response or had refractory lymphoma after at least one prior cytotoxic chemotherapy regimen. Eighteen patients (55%) had received between two and six prior treatment regimens for their lymphoma. Fourteen patients (42%) received a prior anthracycline regimen consisting of either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in ten, ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, etoposide, cytosine arabinoside, bleomycin, vincristine, methotrexate) in two, and CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) or MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) in one patient each The median prior cumulative anthracycline dose was 200 mg/m 2 (range 50-420) Three patients received prior fludarabine alone (n = 2) or in combination with mitoxantrone (n = 1) as their first-line therapy. The remaining 16 patients received an alkylating agent as their initial therapy, consisting of a chlorambucil-containing regimen in 9 or a cyclophosphamide-containing regimen in 7. 
Treatment and dose intensity
A median of six cycles (range 1-15) of liposomal daunorubicin was administered, the median cumulative dose delivered was 560 mg/m 2 (range 100-1740 mg/m 2 ) Thirteen patients (39%) required one dose reduction due to toxicity. In contrast, six patients (18%) were treated with at least one dose escalation to 120 mg/m 2 . The planned dose intensity of the study was 33.3 mg/m 2 / week); the actual median overall dose intensity delivered in these patients was 30 mg/m 2 /week (range 17.4-37.8).
Response
Two patients were inevaluable for response, one had no measurable or evaluable disease at baseline, and one never returned for follow-up or repeat evaluation As shown (Table 2 ), of the 31 evaluable patients, major response (complete and partial responses) was attained in 12 (39%, 95% CI: 22%-58%) patients, including CR in 2 (6%) and PR in 10 (32%). Characteristics of patients who responded are summarized in Table 3 . Maximum objective responses were attained after a median of six cycles (range 2-10) of liposomal daunorubicin Six responders (50%) had received a prior anthracycline. Of note, one of four patients with mantle-cell lymphoma achieved a PR lasting 41+ months. Three patients with intermediate-grade lymphoma also achieved major response, consisting of CR in two patients with follicular large-cell lymphoma, and a PR lasting 26+ months in a patient with diffuse small cleaved lymphoma Responses were seen in 8 of 23 (35%) patients with low-grade lymphoma The overall duration of response was 19 5 months, with a median duration of PR of 20 months (range 4.3-41 1+), and duration of CR of 6 and 29+ months ( Table 3 ). The median time to disease progression in all patients was 9.4 months (range 1-41 1+). A total of nine patients have died; seven of these died of disease progression, two died of events unrelated to disease. 
Toxicitv
All 33 patients were evaluable for toxicity As shown in Table 4 , the most common side effect was bone marrow suppression. Overall, 26 patients (79%) experienced grade 3 or 4 neutropenia. Thirteen patients underwent dose reductions to either 80 mg/m 2 (n = 12) or 60 mg/m 2 (n -1), reductions in eleven of these patients were due to neutropenia; the remainder were for non-hematologic events One patient required one further reduction to 60 mg/m 2 due to recurrent neutropenia. Dose reductions occurred at a median of two cycles (range 2-6) of liposomal daunorubicin. Despite the high rate of neutropenia, there were no reports of hospitalizations for neutropenia, or reports of neutropenic sepsis. Grade 3 or 4 thrombocytopenia and anemia were less common (21% and 15%, respectively). The most frequent nonhematologic toxicities were nausea (67%) and fatigue (49%) Stomatitis was reported in seven patients (21%). There were no episodes of hand-foot syndrome reported.
Five patients experienced cardiotoxicity, with a decline in LVEF to <45% after receiving cumulative doses of liposomal daunorubicin ranging from 500-1740 mg/m 2 . Three of these patients had received prior doxorubicin at cumulative doses of 300, 350 and 400 mg/m 2 , respectively, and the declines in LVEF were not symptomatic in any patient, after cumulative liposomal daunorubicin doses of 840, 620, and 500 mg/m 2 , respectively. One of these patients remains in partial remission off therapy for 26+ months, his LVEF returned to 44% seven months after cessation of therapy. The two remaining were lost to follow-up and did not undergo repeat LVEF.
Two patients experiencing cardiotoxicity had no prior exposure to an anthracycline. One of these patients, a 50-year-old female, received a cumulative dose of 1000 mg/m 2 and experienced a decline in LVEF to 42%, which three months later recovered to normal at 56% The other patient, a 71-year-old male developed congestive heart failure (CHF) after a cumulative liposomal daunorubicin dose of 1740 mg/m He received digitalis and furosemide, and continues to be clinically well compensated, one year after the onset of CHF.
Discussion
The non-Hodgkin's lymphomas are a diverse group of malignancies. Several classification systems have been developed in an attempt to better categorize distinct pathologic entities. In the Working Formulation classification, small lymphocytic, follicular small cleaved, and follicular mixed lymphomas are classified as low-grade lymphomas with an indolent clinical course [13] . However, in the Working Formulation, certain intermediategrade lymphomas including follicular large cell and diffuse small cleaved histologies, are also associated with relatively indolent clinical courses. Further, in the Revised European-American Lymphoma Classification System, several new pathologic types have been identified which have also been associated with an indolent clinical course [14] . These include marginal zone, monocytoid B-cell, or mucosal-associated lymphoid tissue lymphomas [15, 16] Another newly recognized pathologic entity, previously grouped with the indolent lym-phomas, is mantle-cell lymphoma Recent studies have demonstrated that mantle-cell lymphoma carries a very poor prognosis and should not be classified as an indolent lymphoma [16, 17] .
To date, no curative therapy has been identified for patients with indolent lymphoma, although the natural history of disease is prolonged, with median survivals of seven years or more [1, 2] . Despite the prolonged course of disease, most patients will eventually require treatment. Although high response rates can be achieved with single alkylating agents, punne analogs, radiation therapy, or combination chemotherapy [2] [3] [4] [18] [19] [20] [21] , responses are not durable, necessitating use of multiple different regimens over years of intermittent therapy. Monoclonal anti-CD20 therapy with rituximab has recently been studied and found to be effective in relapsed folhcular lymphomas with major response rates of approximately 50% [22] However, the role of rituximab in small lymphocytic lymphoma remains controversial, and despite its activity in other types of indolent lymphoma, rituximab has yet to be associated with long-term disease-free survival
We studied the safety and efficacy of single-agent hposomal daunorubicin in 33 patients with relapsed or refractory indolent lymphoma Liposomal encapsulation of cytotoxic agents has been shown to provide pharmacokinetic advantages, including a prolonged half-life compared with the free drug. In addition, in vitro studies have shown preferential uptake into tumors, including non-Hodgkin's lymphoma [6] . Earlier studies with liposomal daunorubicin have also demonstrated a reduced toxicity profile [8] . We report that liposomal daunorubicin administered intravenously a dose of 100 mg/m 2 every 3 weeks was active in patients with indolent relapsed or refractory non-Hodgkin's lymphomas, producing a major response rate of 39% (2 PR, 10 CR) with a median duration of response of 19 months. Responses occurred in patients with both low-and intermediate-grade lymphomas, in one of four patients with mantle-cell lymphoma and in six (50%) patients who had previously received an anthracychne. The response rate and median disease-free survival are comparable to other active agents used in the treatment of relapsed or refractory non-Hodgkin's lymphoma
The most common adverse effect noted in this study was neutropenia. Grade 3 or 4 neutropema was reported in 79% of patients, although colony-stimulating factors were not given prophylactically, but as clinically indicated after the occurrence of a grade 3 or 4 neutropenic event Notably, none of the neutropenic events were associated with fever or sepsis or required hospitalization Cardiac toxicity was observed in five patients, manifested by a decline in LVEF <45%, asymptomatic in four and associated with clinical CHF in one. All five patients discontinued therapy secondary to the fall in LVEF. While speculative, reducing the high peak drug concentration, which is associated with high risk for cardiac toxicity [23] , by giving lower, more frequent doses, may prevent this toxicity in future patients.
In summary, liposomal daunorubicin has activity in the treatment of patients with refractory or relapsed low-grade, folhcular large-cell, diffuse small cleaved, and mantle-cell NHL. Bone marrow suppression is the dose limiting toxicity. Future studies should explore the use of lower doses, given at more frequent intervals The precise role of liposomal daunorubicin in the management of these patients will depend on its ability to alter survival. Further long-term follow-up of responding patients will be of importance.
